---
title: "Sandoz partners with Adalvo to commercialize semaglutide in Brazil after ANVISA approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294183033.md"
description: "Sandoz has secured marketing authorization in Brazil for Owozy (semaglutide) and partnered with Adalvo to commercialize the product. This deal grants Sandoz rights in an estimated $1.8 billion Brazilian GLP-1 market, with a launch targeted for the second half of 2026. The product utilizes a pre-filled multi-dose disposable pen. Sandoz expects no material financial contribution from this generic semaglutide launch in 2026."
datetime: "2026-07-29T09:30:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294183033.md)
  - [en](https://longbridge.com/en/news/294183033.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294183033.md)
generator: "portal-rs"
---

# Sandoz partners with Adalvo to commercialize semaglutide in Brazil after ANVISA approval

-   Sandoz secured marketing authorization in Brazil for Owozy (semaglutide) to be commercialized through a partnership with Adalvo. \* Deal gives Sandoz commercial rights in an estimated USD 1.8 billion Brazilian GLP-1 market. \* Launch targeted for the second half of 2026; product uses a pre-filled multi-dose disposable pen. \* Sandoz expects no material 2026 financial contribution from any potential generic semaglutide launch. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc\_2373154\_en) on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SDZNY.US](https://longbridge.com/en/quote/SDZNY.US.md)

## Related News & Research

- [Sandoz targets mid-to-high single-digit net sales CAGR in 2025-30, core EBITDA margin 25%-27% by 2030](https://longbridge.com/en/news/298263003.md)
- [Sandoz invests USD 300 million in new biosimilar drug substance facility in Slovenia](https://longbridge.com/en/news/298263480.md)
- [Sandoz focuses on biosimilars to help double group sales by 2035](https://longbridge.com/en/news/298296106.md)
- [4-Sandoz bets big on biosimilars, aims to double group sales by 2035](https://longbridge.com/en/news/298350855.md)
- [RBC Capital Remains a Hold on Sandoz Group Ltd (SDZXF)](https://longbridge.com/en/news/298004740.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**